Press Coverage, BioCentury, Week in Review
BioXcel Corp. (Branford, Conn.) launched new subsidiary BioXcel Therapeutics Inc. (BTI), which will use artificial intelligence-driven R&D to identify indications for candidates that demonstrated safety but not efficacy in Phase II testing or later.
BTI’s pipeline includes BXCL701 — an inhibitor of dipeptidyl peptidase-8 (DPP-9), DPP-9 and fibroblast activation protein (FAP) — as both monotherapy and in combination with immune-checkpoint inhibitors to treat castration resistant prostate cancer (CRPC) and other cancers; and BXCL501, a sublingual formulation of an undisclosed FDA-approved anesthetic that selectively agonizes adrenergic receptor alpha 2a (ADRA2A), to treat acute agitation in schizophrenic and bipolar patients.
By early 2018, BTI plans to begin a proof-of-concept Phase Ib/II trial for BXCL701 and a proof-of-concept trial for the BXCL501. It will pursue approval for BXCL501 under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference data on safety and efficacy from the scientific literature or previously approved products.